Effectiveness of GPOvirS30 for the Treatment of Naïve HIV Patients in Pathumthani Hospital: a 5-Year Experience - ผลการรักษาผู้ติดเชื้อเอชไอวีและผู้ป่วยโรคเอดส์ด้วยยา GPOvirS30 ในโรงพยาบาลปทุมธานี: ประสบการณ์ 5 ปี

Abstract

The quality of life of HIV–infected patients in Thailand has been improved due to widely use of
the antiretroviral drug - GPOvirS30. The incidence of opportunistic infection and mortality rate markedly
decreased. However, compliance and adherence of the treatment were limited by adverse drug
events. The objective of this study was to assess long term effectiveness, side effects and incidence of
immune reconstitution inflammatory syndrome (IRIS) among treatment naïve HIV–infected patients
who were treated with GPOvirS30 during 2002 – 2007 at Pathumthani hospital. There were altogether
148 cases. The Mean (IQR) baseline CD4 cell count was 68.4 cells/mm3 (ranging from 1 – 287).
Treatment effectiveness was observed in 30 cases (20.3%) who had the mean CD4 cell count increased
to 601.8 (243 – 1,402) cells/mm3 after 76.7 months of continuous treatment; and the plasma viral
load was undetectable (lower than 50 copies/ml). Adverse events including lipodystrophy, rash, elevated
ALT and peripheral neuropathy were detected in 43.2%, 13.5%, 11.5% and 8.8% of patients,
respectively. Twenty-six 26 patients (17.5%) receiving GPOvisS30 developed IRIS including tuberculosis
IRIS (8.8%), cryptococcosis IRIS (3.4%) and mycobacterium avium complex IRIS (0.6%).
In conclusion, GPOvirS30 was quite well effective in increasing CD4 cell counts and suppressing plasma
viremia over five years follow–up period. Its important complication, lipodystrophy was an obstacle for
long term compliance. To avoid this problem, further studies to determine risk factors and develop
appropriate screening test are needed.
Key words: HIV infection, GPOvirS30, effectiveness, adverse events